NCT00092196已完成3 期
Open-label Extension to: A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Moderately Emetogenic Chemotherapy
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 820
- 主要终点
- Safety and tolerability
研究概览
简要总结
The purpose of this study is to determine the efficacy and tolerability of an investigational drug for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient with a diagnosis of breast cancer requiring treatment with non-cisplatin moderately emetogenic chemotherapy.
- •Patient must have completed participation in the main study for this protocol.
排除标准
- •Patient has a central nervous system malignancy.
- •Patient will receive radiation to the abdomen or pelvis.
结局指标
主要结局
Safety and tolerability
次要结局
- Assessment of adverse experiences using the National Cancer Institute (NCI) criteria
研究者
相似试验
终止
2 期
Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx)Beta Thalassemia IntermediaNCT04059406Ionis Pharmaceuticals, Inc.29
Unknown
1 期
A Study to Evaluate Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of IN-C005 in Healthy Male SubjectsHealthyNCT04485884HK inno.N Corporation42
进行中（未招募）
1 期
A Study to Evaluate the Safety, Tolerability, PK and PD of Intracerebroventricular GC1123 in Patients with MPS ⅡMucopolysaccharidosis IIHunter SyndromeNCT05422482GC Biopharma Corp12
已完成
4 期
Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary ImmunodeficiencyPrimary ImmunodeficiencyNCT01465958Grifols Therapeutics LLC12
已完成
1 期
Safety, Tolerability and Pharmacokinetics of Different Multiple Doses of BI 207127 BID and Multiple Doses of BI 207127 Combined With Faldaprevir in Healthy Male and Female SubjectsHealthyNCT01737996Boehringer Ingelheim32